Cardiology Research and Practice [73] R. Shibata, N. Ouchi, M. Ito et al., “Adiponectin-mediated modulation of hypertrophic signals in the heart,” Nature Medicine, vol. 10, no. 12, pp. 1384–1389, 2004. [74] F. Dong and J. Ren, “Adiponectin improves cardiomyocyte contractile fnction in db/db diabetic obese mice,” Obesity, vol. 17, no. 2, pp. 262–268, 2009. [75] N. Ouchi, S. Kihara, T. Funahashi, Y. Matsuzawa, and K. Walsh, “Obesity, adiponectin and vascular inﬂammatory disease,” Current Opinion in Lipidology, vol. 14, no. 6, pp. 561–566, 2003. [76] H. Chen, M. Montagnani, T. Funahashi, I. Shimomura, and M. J. Quon, “Adiponectin stimulates production of nitric oxide in vascular endothelial cells,” Journal of Biological Chemistry, vol. 278, no. 45, pp. 45021–45026, 2003. [77] K. K. Y. Cheng, K. S. L. Lam, Y. Wang et al., “Adiponectin- induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothe- lial cells,” Diabetes, vol. 56, no. 5, pp. 1387–1394, 2007. [78] S. J. Hong, C. G. Park, H. S. Seo, D. J. Oh, and Y. M. Ro, “Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index,” Blood Pressure, vol. 13, no. 4, pp. 236–242, 2004. [79] P. C. Schulze, J. Kratzsch, A. Linke et al., “Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure,” European Journal of Heart Failure, vol. 5, no. 1, pp. 33–40, 2003. [80] S. So¨derberg, B. Ahre´n, J. H. Jansson et al., “Leptin is associated with increased risk of myocardial infarction,” Journal of Internal Medicine, vol. 246, no. 4, pp. 409–418, 1999. [81] A. M. Wallace, A. D. McMahon, C. J. Packard et al., “Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS),” Circulation, vol. 104, no. 25, pp. 3052–3056, 2001. [82] D. E. Flanagan, J. C. Vaile, G. W. Petley et al., “Gender dif- ferences in the relationship between leptin, insulin resistance and the autonomic nervous system,” Regulatory Peptides, vol. 140, no. 1-2, pp. 37–42, 2007. [83] C. Menendez, R. Baldelli, M. Lage et al., “The in vitro secre- tion of human leptin is gender-dependent but independent of the body mass index of the donors,” European Journal of Endocrinology, vol. 143, no. 5, pp. 711–714, 2000. [84] P. F. Bodary, R. J. Westrick, K. J. Wickenheiser, Y. Shen, and D. T. Eitzman, “Eﬀect of leptin on arterial thrombosis following vascular injury in mice,” Journal of the American Medical Association, vol. 287, no. 13, pp. 1706–1709, 2002. [85] J. P. Cooke and R. K. Oka, “Does leptin cause vascular disease?” Circulation, vol. 106, no. 15, pp. 1904–1905, 2002. [86] G. N. Chaldakov, M. Fiore, I. S. Stankulov et al., “NGF, BDNF, leptin, and mast cells in human coronary atheroscle- rosis and metabolic syndrome,” Archives of Physiology and Biochemistry, vol. 109, no. 4, pp. 357–360, 2001. [87] N.-F. Chu, D. Spiegelman, N. Rifai, G. S. Hotamisligil, and E. B. Rimm, “Glycemic status and soluble tumor necrosis factor receptor levels in relation to plasma leptin concentrations among normal weight and overweight US men,” International Journal of Obesity, vol. 24, no. 9, pp. 1085–1092, 2000. [88] M. R. Sierra-Honigmann, A. K. Nath, C. Murakami et al., “Biological action of leptin as an angiogenic factor,” Science, vol. 281, no. 5383, pp. 1683–1686, 1998. [89] A. Singhal, S. Farooqi, T. J. Cole et al., “Inﬂuence of leptin on arterial distensibility: a novel link between obesity and 9 cardiovascular disease?” Circulation, vol. 106, no. 15, pp. 1919–1924, 2002. [90] N. Nagaya, M. Uematsu, M. Kojima et al., “Elevated circulat- ing level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors,” Circulation, vol. 104, no. 17, pp. 2034–2038, 2001. [91] S. Frascarelli, S. Ghelardoni, S. Ronca-Testoni, and R. Zucchi, “Eﬀect of ghrelin and synthetic growth hormone secreta- gogues in normal and ischemic rat heart,” Basic Research in Cardiology, vol. 98, no. 6, pp. 401–405, 2003. [92] N. Nagaya, M. Uematsu, M. Kojima et al., “Chronic admin- istration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure,” Circulation, vol. 104, no. 12, pp. 1430–1435, 2001. [93] N. Nagaya, M. Kojima, M. Uematsu et al., “Hemodynamic and hormonal eﬀects of human ghrelin in healthy volun- teers,” American Journal of Physiology - Regulatory Integrative and Comparative Physiology, vol. 280, no. 5, pp. R1483– R1487, 2001. [94] N. Nagaya and K. Kangawa, “Therapeutic potential of Ghrelin in the treatment of heart failure,” Drugs, vol. 66, no. 4, pp. 439–448, 2006. [95] N. Nagaya, K. Miyatake, M. Uematsu et al., “Hemodynamic, renal, and hormonal eﬀects of ghrelin infusion in patients with chronic heart failure,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 12, pp. 5854–5859, 2001. [96] N. Nagaya, J. Moriya, Y. Yasumura et al., “Eﬀects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure,” Circulation, vol. 110, no. 24, pp. 3674–3679, 2004. [97] N. Kamei, K. Tobe, R. Suzuki et al., “Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance,” Journal of Biological Chemistry, vol. 281, no. 36, pp. 26602– 26614, 2006. [98] H. Xu, G. T. Barnes, Q. Yang et al., “Chronic inﬂammation in fat plays a crucial role in the development of obesity-related insulin resistance,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1821–1830, 2003. [99] S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante, “Obesity is associated with macrophage accumulation in adipose tissue,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003. [100] J. R. Sowers, “Metabolic risk factors and renal disease,” Kidney International, vol. 71, no. 8, pp. 719–720, 2007. [101] S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante Jr., “Obesity is associated with macrophage accumulation in adipose tissue,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003. [102] C. A. Curat, A. Miranville, C. Sengene`s et al., “From blood monocytes to adipose tissue-resident macrophages: induc- tion of diapedesis by human mature adipocytes,” Diabetes, vol. 53, no. 5, pp. 1285–1292, 2004. [103] R. Cancello, J. Tordjman, C. Poitou et al., “Increased inﬁltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity,” Diabetes, vol. 55, no. 6, pp. 1554–1561, 2006. [104] G. Zeng, F. H. Nystrom, L. V. Ravichandran et al., “Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells,” Circulation, vol. 101, no. 13, pp. 1539–1545, 2000.